These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17428857)

  • 1. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.
    Chinnadurai R; Rajan D; Münch J; Kirchhoff F
    J Virol; 2007 Jun; 81(12):6563-72. PubMed ID: 17428857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B
    J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.
    Wang W; De Feo CJ; Zhuang M; Vassell R; Weiss CD
    J Virol; 2011 Dec; 85(24):12929-38. PubMed ID: 21994458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
    Lohrengel S; Hermann F; Hagmann I; Oberwinkler H; Scrivano L; Hoffmann C; von Laer D; Dittmar MT
    J Virol; 2005 Aug; 79(16):10237-46. PubMed ID: 16051817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
    Xu L; Pozniak A; Wildfire A; Stanfield-Oakley SA; Mosier SM; Ratcliffe D; Workman J; Joall A; Myers R; Smit E; Cane PA; Greenberg ML; Pillay D
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1113-9. PubMed ID: 15728911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
    Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
    Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.
    Eggink D; Langedijk JP; Bonvin AM; Deng Y; Lu M; Berkhout B; Sanders RW
    J Biol Chem; 2009 Sep; 284(39):26941-50. PubMed ID: 19617355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.
    Morozov VA; Morozov AV; Schürmann D; Jessen H; Kücherer C
    Virus Genes; 2007 Oct; 35(2):167-74. PubMed ID: 17440804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.
    Eggink D; Bontjer I; Langedijk JP; Berkhout B; Sanders RW
    J Virol; 2011 Oct; 85(20):10785-97. PubMed ID: 21835789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
    FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.